PepGen IPO Marks Major Milestone for Next-Gen Gene Therapy Technology

Clinical-stage biotech firm PepGen has successfully priced its public offering at $3.20 per share, raising approximately $100 million in gross proceeds. The offering comprises 31.25 million shares and represents a significant vote of confidence in the company’s innovative approach to treating severe neuromuscular and neurological conditions.

Capital Raise Details and Timeline

The IPO, led by joint bookrunning managers Leerink Partners and Stifel, is set to close around September 26, 2025, pending standard closing conditions. Underwriters have also secured a 30-day option to purchase an additional 4.69 million shares at the public offering price minus underwriting discounts, providing additional upside potential.

Strategic Use of Proceeds

PepGen intends to deploy the capital toward advancing its clinical pipeline, specifically funding the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials. Beyond immediate research needs, the company will allocate resources toward general working capital and corporate infrastructure to support its growth trajectory.

Technology Platform Advantage

At the core of PepGen’s strategy lies the Enhanced Delivery Oligonucleotide (EDO) platform, developed over more than a decade of research. This proprietary technology leverages cell-penetrating peptides to enhance the bioavailability and efficacy of oligonucleotide therapeutics—a critical advancement in treating conditions that have historically posed significant treatment challenges.

The EDO platform positions PepGen to address the root causes of severe diseases through a pipeline of next-generation oligonucleotide candidates, potentially transforming treatment paradigms in neuromuscular and neurological disease management.

Forward-Looking Considerations

While the offering represents a positive catalyst for PepGen’s development stage initiatives, investors should note that completion remains subject to customary closing conditions and broader market dynamics. The company’s success will ultimately depend on clinical trial outcomes and regulatory pathway execution.